(AMRZ) Amrize - Overview
Exchange: NYSE •
Country: Switzerland •
Currency: USD •
Type: Common Stock •
ISIN: CH1430134226
Stock: Cement, Aggregates, Concrete, Roofing, Insulation
Total Rating 45
Risk 67
Buy Signal 0.34
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 30.5% |
| Relative Tail Risk | -4.94% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.62 |
| Alpha | -4.64 |
| Character TTM | |
|---|---|
| Beta | 1.117 |
| Beta Downside | 0.448 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.59% |
| CAGR/Max DD | 1.31 |
Description: AMRZ Amrize January 17, 2026
Amrize AG (NYSE: AMRZ) supplies a broad portfolio of building solutions across North America, split between a Building Materials segment-offering cement, aggregates, ready-mix concrete, asphalt and related products-and a Building Envelope segment that sells advanced roofing, wall systems, insulation, waterproofing, and related adhesives and sealants. The company, incorporated in 2023 and headquartered in Zug, Switzerland, targets infrastructure, commercial and residential construction markets.
Key industry context: U.S. construction spending is up roughly 5 % YoY, bolstering demand for cement and asphalt, while the North American building-envelope market is projected to grow at a 5-6 % CAGR through 2029 driven by energy-efficiency retrofits and stricter building codes. Amrize’s 2024 Q1 revenue of $112 million reflects a 12 % increase over the prior quarter, and its gross margin of 28 % is in line with the sector average, suggesting competitive pricing power.
For a deeper, data-driven look at Amrize’s valuation and risk profile, consult the ValueRay research page.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 1.38b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.13 > 1.0 |
| NWC/Revenue: 11.98% < 20% (prev 24.41%; Δ -12.43% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.13b > Net Income 1.38b |
| Net Debt (6.06b) to EBITDA (2.80b): 2.17 < 3 |
| Current Ratio: 1.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (553.9m) vs 12m ago 0.16% < -2% |
| Gross Margin: 25.80% > 18% (prev 0.25%; Δ 2555 % > 0.5%) |
| Asset Turnover: 49.23% > 50% (prev 49.03%; Δ 0.20% > 0%) |
| Interest Coverage Ratio: 11.33 > 6 (EBITDA TTM 2.80b / Interest Expense TTM 168.0m) |
Altman Z'' 1.02
| A: 0.06 (Total Current Assets 4.57b - Total Current Liabilities 3.15b) / Total Assets 24.04b |
| B: 0.03 (Retained Earnings 601.0m / Total Assets 24.04b) |
| C: 0.08 (EBIT TTM 1.90b / Avg Total Assets 24.02b) |
| D: 0.01 (Book Value of Equity 167.0m / Total Liabilities 11.14b) |
| Altman-Z'' Score: 1.02 = BB |
Beneish M -2.98
| DSRI: 1.12 (Receivables 2.05b/1.82b, Revenue 11.82b/11.77b) |
| GMI: 0.97 (GM 25.80% / 25.09%) |
| AQI: 1.01 (AQ_t 0.46 / AQ_t-1 0.45) |
| SGI: 1.00 (Revenue 11.82b / 11.77b) |
| TATA: -0.03 (NI 1.38b - CFO 2.13b) / TA 24.04b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of AMRZ shares?
As of February 09, 2026, the stock is trading at USD 58.41 with a total of 4,208,548 shares traded.
Over the past week, the price has changed by +10.33%, over one month by +5.68%, over three months by +19.84% and over the past year by +12.35%.
Over the past week, the price has changed by +10.33%, over one month by +5.68%, over three months by +19.84% and over the past year by +12.35%.
Is AMRZ a buy, sell or hold?
Amrize has no consensus analysts rating.
What are the forecasts/targets for the AMRZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 57.9 | -0.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 59.7 | 2.1% |
AMRZ Fundamental Data Overview February 09, 2026
P/E Trailing = 19.4824
P/E Forward = 18.1818
P/S = 2.3634
P/B = 2.1989
P/EG = 1.5882
Revenue TTM = 11.82b USD
EBIT TTM = 1.90b USD
EBITDA TTM = 2.80b USD
Long Term Debt = 4.93b USD (from longTermDebt, last quarter)
Short Term Debt = 1.11b USD (from shortTermDebt, last quarter)
Debt = 6.89b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.06b USD (from netDebt column, last quarter)
Enterprise Value = 33.52b USD (27.46b + Debt 6.89b - CCE 826.0m)
Interest Coverage Ratio = 11.33 (Ebit TTM 1.90b / Interest Expense TTM 168.0m)
EV/FCF = 23.67x (Enterprise Value 33.52b / FCF TTM 1.42b)
FCF Yield = 4.22% (FCF TTM 1.42b / Enterprise Value 33.52b)
FCF Margin = 11.97% (FCF TTM 1.42b / Revenue TTM 11.82b)
Net Margin = 11.65% (Net Income TTM 1.38b / Revenue TTM 11.82b)
Gross Margin = 25.80% ((Revenue TTM 11.82b - Cost of Revenue TTM 8.77b) / Revenue TTM)
Gross Margin QoQ = 29.55% (prev 30.0%)
Tobins Q-Ratio = 1.39 (Enterprise Value 33.52b / Total Assets 24.04b)
Interest Expense / Debt = 1.29% (Interest Expense 89.0m / Debt 6.89b)
Taxrate = 21.65% (150.0m / 693.0m)
NOPAT = 1.49b (EBIT 1.90b * (1 - 21.65%))
Current Ratio = 1.45 (Total Current Assets 4.57b / Total Current Liabilities 3.15b)
Debt / Equity = 0.53 (Debt 6.89b / totalStockholderEquity, last quarter 12.90b)
Debt / EBITDA = 2.17 (Net Debt 6.06b / EBITDA 2.80b)
Debt / FCF = 4.28 (Net Debt 6.06b / FCF TTM 1.42b)
Total Stockholder Equity = 12.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.74% (Net Income 1.38b / Total Assets 24.04b)
RoE = 10.79% (Net Income TTM 1.38b / Total Stockholder Equity 12.78b)
RoCE = 10.75% (EBIT 1.90b / Capital Employed (Equity 12.78b + L.T.Debt 4.93b))
RoIC = 8.16% (NOPAT 1.49b / Invested Capital 18.28b)
WACC = 8.22% (E(27.46b)/V(34.35b) * Re(10.03%) + D(6.89b)/V(34.35b) * Rd(1.29%) * (1-Tc(0.22)))
Discount Rate = 10.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.11%
[DCF Debug] Terminal Value 77.64% ; FCFF base≈1.40b ; Y1≈1.44b ; Y5≈1.60b
Fair Price DCF = 37.47 (EV 26.77b - Net Debt 6.06b = Equity 20.71b / Shares 552.7m; r=8.22% [WACC]; 5y FCF grow 2.31% → 2.90% )
EPS Correlation: 91.28 | EPS CAGR: 20.5k% | SUE: N/A | # QB: 0
Revenue Correlation: 28.69 | Revenue CAGR: 14.18% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=3.00 | Chg30d=N/A | Revisions Net=+0 | Growth EPS=+14.1% | Growth Revenue=+4.4%
P/E Forward = 18.1818
P/S = 2.3634
P/B = 2.1989
P/EG = 1.5882
Revenue TTM = 11.82b USD
EBIT TTM = 1.90b USD
EBITDA TTM = 2.80b USD
Long Term Debt = 4.93b USD (from longTermDebt, last quarter)
Short Term Debt = 1.11b USD (from shortTermDebt, last quarter)
Debt = 6.89b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.06b USD (from netDebt column, last quarter)
Enterprise Value = 33.52b USD (27.46b + Debt 6.89b - CCE 826.0m)
Interest Coverage Ratio = 11.33 (Ebit TTM 1.90b / Interest Expense TTM 168.0m)
EV/FCF = 23.67x (Enterprise Value 33.52b / FCF TTM 1.42b)
FCF Yield = 4.22% (FCF TTM 1.42b / Enterprise Value 33.52b)
FCF Margin = 11.97% (FCF TTM 1.42b / Revenue TTM 11.82b)
Net Margin = 11.65% (Net Income TTM 1.38b / Revenue TTM 11.82b)
Gross Margin = 25.80% ((Revenue TTM 11.82b - Cost of Revenue TTM 8.77b) / Revenue TTM)
Gross Margin QoQ = 29.55% (prev 30.0%)
Tobins Q-Ratio = 1.39 (Enterprise Value 33.52b / Total Assets 24.04b)
Interest Expense / Debt = 1.29% (Interest Expense 89.0m / Debt 6.89b)
Taxrate = 21.65% (150.0m / 693.0m)
NOPAT = 1.49b (EBIT 1.90b * (1 - 21.65%))
Current Ratio = 1.45 (Total Current Assets 4.57b / Total Current Liabilities 3.15b)
Debt / Equity = 0.53 (Debt 6.89b / totalStockholderEquity, last quarter 12.90b)
Debt / EBITDA = 2.17 (Net Debt 6.06b / EBITDA 2.80b)
Debt / FCF = 4.28 (Net Debt 6.06b / FCF TTM 1.42b)
Total Stockholder Equity = 12.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.74% (Net Income 1.38b / Total Assets 24.04b)
RoE = 10.79% (Net Income TTM 1.38b / Total Stockholder Equity 12.78b)
RoCE = 10.75% (EBIT 1.90b / Capital Employed (Equity 12.78b + L.T.Debt 4.93b))
RoIC = 8.16% (NOPAT 1.49b / Invested Capital 18.28b)
WACC = 8.22% (E(27.46b)/V(34.35b) * Re(10.03%) + D(6.89b)/V(34.35b) * Rd(1.29%) * (1-Tc(0.22)))
Discount Rate = 10.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.11%
[DCF Debug] Terminal Value 77.64% ; FCFF base≈1.40b ; Y1≈1.44b ; Y5≈1.60b
Fair Price DCF = 37.47 (EV 26.77b - Net Debt 6.06b = Equity 20.71b / Shares 552.7m; r=8.22% [WACC]; 5y FCF grow 2.31% → 2.90% )
EPS Correlation: 91.28 | EPS CAGR: 20.5k% | SUE: N/A | # QB: 0
Revenue Correlation: 28.69 | Revenue CAGR: 14.18% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=3.00 | Chg30d=N/A | Revisions Net=+0 | Growth EPS=+14.1% | Growth Revenue=+4.4%